NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NeuroMetrix stock opened at $3.53 on Friday. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $6.40. The firm has a 50 day moving average price of $3.55 and a 200 day moving average price of $3.77. The company has a market cap of $7.10 million, a price-to-earnings ratio of -0.56 and a beta of 2.30.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Cerity Partners LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned 2.80% of NeuroMetrix as of its most recent SEC filing. Institutional investors own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.